– U.S. FDA has confirmed that screening and dosing may proceed in Study SRP-9005-101 for LGMD2C/R5 – Enrollment and dosing completed in Study SRP-9004-102 for LGMD2D/R3 – Data expected for SRP-9003 ...
Data are scarce regarding the benefits of strength training for muscular dystrophies, for which there are no cures. Strength training to ameliorate the effects of muscular dystrophies (MDs) was found ...
BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced an expansion of their clinical development program of ...
FDA and Capricor aligned on endpoints for HOPE-3 pivotal trialHOPE-3 pivotal trial completed; topline data expected mid-Q4 2025 to support BLA ...
SAN DIEGO, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (CAPR) (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of ...
New York, Jan. 13, 2025 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) is proud to announce that applications are now open for the second year of the MDA College Scholarship Program.
May 24, 2024 – Boston, Mass. — hC Bioscience, a biopharmaceutical company developing a fundamentally novel approach to treating genetic diseases through tRNA-based protein editing, today announced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback